Antibacterial Resistance
Antibacterial resistance remains an urgent public health concern even in New Zealand. While overall resistance rates here are lower than in some neighbouring regions, resistant strains of bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenemase-producing organisms are increasingly detected in both hospital and community settings, and the proportion of resistant infections continues to rise despite historical low prevalence. Up to 14 percent of isolates in a national point prevalence survey demonstrated antimicrobial resistance, including methicillin-resistant S. aureus and cephalosporin- or carbapenem-resistant Gram-negative bacilli.
Translyx is working to bring diagnostic technologies that enable faster, more precise identification of resistant pathogens and key resistance markers. These tools support better antimicrobial stewardship by helping clinicians refine therapy choices earlier in the care pathway, reduce unnecessary antibiotic use, and strengthen surveillance capability across primary and hospital care. By improving diagnostic intelligence on resistance patterns, Translyx contributes to slowing the spread of resistant infections and protecting the effectiveness of existing therapies locally and regionally.